百令胶囊对腹膜透析患者腹透液中间皮细胞转化生长因子β1水平的影响

Effect of Bailing Capsules on the Expressing of TGF-β1 in the Peritoneal Dialysis Solution for Peritoneal Dialysis Patients

目的:观察百令胶囊对腹膜透析患者腹透液中间皮细胞转化生长因子β1(TGF-β1)水平的影响。方法:40例行腹膜透析的患者随机分为对照组和试验组各20例,两组均应用1.5%腹膜透析液,6 000 ml·d^(-1),试验组再加用百令胶囊2.5g,po,tid,共观察6个月。1个月时评估两组透析充分性[指标:尿素清除指数(Kt/V)及内生肌酐清除率(Ccr)],比较两组患者1,3,6个月时肾功能及腹透液中TGF-β1水平变化。结果:透析1个月时,两组Kt/V及Ccr比较无差异,血肌酐均明显降低(P<0.05),3,6个月两组血肌酐水平无明显波动。对照组1,3,6个月TGF-β1水平逐渐升高(P<0.05),试验组TGF-β1水平无明显变化(P>0.05),且明显低于对照组(P<0.05)。结论:口服百令胶囊可降低患者腹透液中TGF-β1水平,从而抑制腹膜纤维化的发展。

Objective： To investigate the effects of Bailing capsules on the expression of TGF-β1 in the peritoneal dialysis solution for peritoneal dialysis patients. Methods： Totally 40 patients treated with peritoneal dialysis（ PD） were randomly divided into two groups（20 cases in the control group and 20 cases in the experimental group）. All the patients were treated with PD by 1. 5% peritoneal dialysis effluent（6 000 ml everyday）,and the patients in the experimental group were additionally treated with Bailing capsules（5 capsules each time,three times a day after meals） for 6 months. The adequacy of PD（including Kt/V and Ccr） of the two groups was examined after the one-month treatment. The renal function and the level of TGF-β1 in the effluent in 1,3 and 6 month were compared between the two groups. Results： The adequacy of PD（ Kt / V and Ccr） had no significant difference between the two groups（P 〈0. 05）. The level of serum creatine was decreased significantly in both groups after the one-month treatment（P 〈0. 05）,and no significant change was shown in 3 and 6 month（ P 〉0. 05）. In the control group,the expression of TGF-β1 in the effluent in 1,3 and6 month was increased gradually with significant difference（ P 〈0. 05）. In the experimental group,the expression of TGF-β1 in the effluent had no significant difference in 1,3 and 6 month（ P 〉0. 05）,which was lower than that in the control group（ P〈0. 05）.Conclusion： Bailing capsules can decrease the expression of TGF-β1 in the effluent for the patients treated with PD and inhibit the peritoneal fibrosis.